TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19099294
Drug: Cannabis cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis cigarettes containing 69.4 mg THC
Study: 16469601
Drug: Tolterodine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (2 mg twice daily)
Study: 15223887
Drug: Topical analgesic
Normalized name: Tricylate 2%-10% Topical Analgesic Cream
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical analgesic
Study: 9234921
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (cisplatin, vincristine, and bleomycin every 3 weeks for four courses)
Study: 8215728
Drug: Nortriptyline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (50 to 150 mg/mL for 6 weeks)
Study: 29289540
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg/d (n=67)
Study: 29289540
Drug: Glargine at
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glargine at a starting dose of 0.1 U/kg/d (n=73)
Study: 29289540
Drug: Glargine at
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glargine at a starting dose of 0.1 U/kg/d
Study: 27474257
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of the proton pump inhibitor (rabeprazole)
Study: 24743122
Drug: Standard procedure
Normalized name: HOMOSALATE 60 mg in 1 mL / OCTOCRYLENE 30 mg in 1 mL / ZINC OXIDE 80 mg in 1 mL TOPICAL STICK [Standard Procedure Lip Balm SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard procedure (Antibiotics, systemic metronidazole, antihistamines, traditional external therapy)
Study: 24743122
Drug: Rutin Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rutin Forte (2 capsules per day)
Study: 22023376
Drug: Carbohydrate intake,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate intake, insulin boluses, and bouts of exercise
Study: 22023376
Drug: 10-min plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-min plasma glucose measurements and plasma insulin and glucagon analyses
Study: 20123226
Drug: rt‐PA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA treatment between 0401 and 0800 hours
Study: 20123226
Drug: rt‐PA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA treatment between 0000 and 0400 hours
Study: 20123226
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with stroke onset between 1801 and 2400 hours
Study: 12970212
Drug: Low-dose target
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose target range (INR 1.8 to 2.8 for aortic position and 2.5 to 3.5 for mitral position)
Study: 31831073
Drug: SPIN-SSLED Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPIN-SSLED Program (13-module training delivered via webinar over 3 months in weekly 60-90 minute sessions)
Study: 29074542
Drug: Inhaled RV568
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled RV568 (50 µg)
Study: 29074542
Drug: Inhaled RV568
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled RV568 (100 µg)
Study: 29074542
Drug: Inhaled RV568
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled RV568
Study: 18561007
Drug: Self-Administered Interview
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Administered Interview (SAI)
Study: 15832861
Drug: Face Former
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face Former therapy
Study: 15832861
Drug: Conventional myofunctional
Normalized name: Bifunctional epoxide hydrolase 2
DrugBank: Bifunctional epoxide hydrolase 2 (DB15139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional myofunctional therapy (Control)
Study: 15896747
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1,500 mg twice a day
Study: 15896747
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 1.5 to 3 mg/kg in 4 daily doses
Study: 8726758
Drug: NaP solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaP solution
Study: 6758252
Drug: Three-times-weekly regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-times-weekly regimens containing isoniazid, rifampicin, and streptomycin and pyrazinamide (regimen 1)
Study: 6758252
Drug: Three-times-weekly regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-times-weekly regimens containing isoniazid, rifampicin, and streptomycin (regimen 2)
Study: 6758252
Drug: Daily regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol
Study: 6758252
Drug: Three-times-weekly regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-times-weekly regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (regimen 4)
Study: 6758252
Drug: Three-times-weekly regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-times-weekly regimen of isoniazid, rifampicin, and ethambutol (regimen 3)
Study: 31094782
Drug: Buccal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal oxygen administration
Study: 24735005
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 0.4% (n=37), administered 4 times daily for 3 days before surgery and 5 weeks postoperatively.
Study: 24735005
Drug: Hypromellose/dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypromellose/dextran 70 as a placebo (n=44), administered 4 times daily for 3 days before surgery and 5 weeks postoperatively.
Study: 20064211
Drug: CAT-354 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAT-354 (1 mg/kg, 5 mg/kg, or 10 mg/kg)
Study: 18330081
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal doxorubicin (40 mg/m2) administered intravenously at 4 week intervals
Study: 9290119
Drug: Beta-carotene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (30 mg/day)
Study: 30194492
Drug: BRN-01 homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRN-01 homeopathic medicine complex (Actheane®)
Study: 29716492
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.2% ropivacaine via adductor canal catheter for five days
Study: 29716492
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.2% ropivacaine via adductor canal catheter for three days
Study: 26988768
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg.kg(‐1) body mass plus 0.1 g.kg(‐1) body mass sodium chloride)
Study: 26988768
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g.kg(‐1) body mass)
Study: 26988768
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g.kg(‐1) body mass) plus caffeine (5 mg.kg(‐1) body mass)
Study: 26988768
Drug: Placebo (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.1 g.kg(‐1) body mass sodium chloride)
Study: 22528506
Drug: Metoprolol formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol formulations (100 mg) - slow, moderate, and fast releasing
Study: 22528506
Drug: Synthetic solution
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic solution method
Study: 22528506
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution data
Study: 19040679
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium extended-release (initiated at 500 mg/day for 15 days, then increased to 1000 mg daily, with adjustments permitted within a dosing range of 250-1000 mg daily)
Study: 19040679
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium extended-release
Study: 15312855
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1,200 mg orally twice daily; NAC group; n = 97
Study: 9692411
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg twice daily until delivery)
Study: 9692411
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (nifedipine given if diastolic pressure exceeded 110 mmHg)
Study: 24035531
Drug: BCI-L (Breast-Cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCI-L (Breast-Cancer Index - Linear)
Study: 18171334
Drug: Intramuscular antivenom
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular antivenom (one or two vials)
Study: 18171334
Drug: Intravenous antivenom
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antivenom (one vial or two or more vials)
Study: 16879942
Drug: 150 ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml, 240 mg/ml at 4 ml/s
Study: 16879942
Drug: 120 ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 ml, 300 mg/ml at 4 ml/s
Study: 16879942
Drug: 97.3 ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 97.3 ml, 370 mg/ml at 4 ml/s
Study: 16879942
Drug: 150 ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml, 240 mg/ml at 5 ml/s
Study: 16879942
Drug: 120 ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 ml, 300 mg/ml, 60 ml at 6 ml/s, 60 ml at 3 ml/s
Study: 16879942
Drug: 97.3 ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 97.3 ml, 370 mg/ml at 3.3 ml/s
Study: 16879942
Drug: Constant iodine
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant iodine administration rates (groups II, IV and VI)
Study: 12807165
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation powder (Pulmicort Turbuhaler), 100-800 microg b.i.d. for 52 weeks
Study: 12807165
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation powder (Pulmicort Turbuhaler)
Study: 8888715
Drug: Telenzepine (M1‐muscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine (M1‐muscarinic receptor antagonist)
Study: 1891575
Drug: Psychodynamic, time-limited
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic, time-limited group therapy
Study: 20521324
Drug: Lorazepam (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (acute dose)
Study: 8038589
Drug: Double perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double perfusion schedule with melphalan (6 mg/l limb volume for first perfusion, 9 mg/l for second perfusion, normothermic, 1 hour duration, 3-4 weeks interval)
Study: 8038589
Drug: Single perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single perfusion procedure with melphalan (10 mg/l, normothermic, 1 hour duration)
Study: 2498532
Drug: Intravesical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical mitomycin C (40 mg)
Study: 949902
Drug: gefarnate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: gefarnate (600 mg daily)
Study: 949902
Drug: dummy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: dummy treatment
Study: 30531772
Drug: Venarus and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venarus and compression therapy
Study: 19737089
Drug: PHD inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHD inhibitors
Study: 15933281
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment implemented three times per week for 20 to 30 min each session for 3 months
Study: 12783289
Drug: Ibandronate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (2 or 4 mg)
Study: 12783289
Drug: Pamidronate (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (15, 30, 60, or 90 mg)
Study: 10943910
Drug: Dextromethorphan (non-competitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (non-competitive NMDA antagonist)
Study: 1644724
Drug: Nortriptyline (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (not specified dosage or duration)
Study: 6131825
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active drugs (Quazepam and Flunitrazepam)
Study: 6131825
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs tested (Quazepam and Flunitrazepam)
Study: 25218717
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (PLA, DECAF, CAF, COF)
Study: 27885751
Drug: Optimal Pharmacologic
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Pharmacologic Therapy (OPT)
Study: 21142736
Drug: 810-nm diode
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 810-nm diode laser treatment
Study: 18097896
Drug: Intramuscular ergometrine
Normalized name: Ergometrine
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ergometrine (500 microg) during abdominal closure
Study: 18097896
Drug: Routine bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine bolus dose of 5 units of oxytocin after delivery
Study: 12170143
Drug: Intravenous MgSO(4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous MgSO(4) with carbogen inhalation
Study: 11769996
Drug: Carbogen inhalation
Normalized name: carbogen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbogen inhalation
Study: 2893560
Drug: Intramuscular buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular buprenorphine 0.3 mg
Study: 19464064
Drug: Bosentan 62.5
Normalized name: bosentan 62.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 62.5 mg bid for four weeks (uptitrated to 125 mg bid thereafter)
Study: 15901290
Drug: Levovist 1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levovist 1 g
Study: 15901290
Drug: Sono Vue
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sono Vue 1 mL
Study: 9395700
Drug: Therapeutic touch
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic touch (TT) therapy
Study: 8388479
Drug: All-trans-retinoic acid
Normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans-retinoic acid (all-trans-RA) at a dose of 156 mg/m2 on day 28 and 78 mg/m2 on day 29.
Study: 8388479
Drug: All-trans-retinoic acid
Normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans-retinoic acid (all-trans-RA) at a dose of 78 mg/m2 on day 28 and 156 mg/m2 on day 29.
Study: 11449752
Drug: Family-involved treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-involved treatments
Study: 31477086
Drug: Intensive personalized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive personalized modular outpatient treatment
Study: 30563642
Drug: Esomeprazole and
Normalized name: Esomeprazole and naproxen only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole and Aspirin
Study: 17103286
Drug: Ultrasound guided‐percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided‐percutaneous drainage and i.v. antibiotics (ampicillin, cefuroxime, and metronidazole)
Study: 2683921
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (20 1-g capsules for 12 weeks)
Study: 30326006
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) 400 mg to 800 mg 3 times a day for 8 weeks
Study: 30326006
Drug: Pregabalin (PGB)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (PGB) 150 mg to 300 mg twice daily for 8 weeks
Study: 23224298
Drug: COX‐2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX‐2 inhibitor (Celecoxib)
Study: 19290689
Drug: Behavioral Naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Naltrexone Therapy (BNT)
Study: 11783256
Drug: Integrated Traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Traditional Chinese and Western medicine (TCM-WM)
Study: 2009146
Drug: Delapril (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril (15 mg twice daily)
Study: 2009146
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg daily, with potential doubling of dose if necessary)
Study: 2009146
Drug: Delapril and
Normalized name: delapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril and Enalapril with addition of hydrochlorothiazide (25 mg daily if target not reached)
Study: 31912678
Drug: ddPC (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddPC (weekly paclitaxel and 3-weekly carboplatin)
Study: 17065166
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of morphine (0.15 mg kg(‐1))
Study: 7942653
Drug: Cervical headgear/lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical headgear/lower utility arch combination (CHG/LUA)
Study: 3064717
Drug: Chemotherapy (5-FU)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (5-FU)
Study: 31791675
Drug: Ketamine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (single subanesthetic-dose intravenous infusion)
Study: 17208413
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg/day plus celecoxib 400 mg/day (200 mg bid)
Study: 11423506
Drug: Nateglinide (60,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (60, 120, or 180 mg)
Study: 11423506
Drug: Nateglinide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (60 mg)
Study: 11423506
Drug: Nateglinide (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (180 mg)
Study: 11423506
Drug: Nateglinide (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (higher doses)
Study: 11229181
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (300 mg/day for 15 days)
Study: 2758752
Drug: Out-patient lumbar
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-patient lumbar radiculography with 10 ml iohexol (240 mgI/ml)
Study: 19966701
Drug: Minimally invasive,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive, endovascular methods of treatment
Study: 16723553
Drug: Voriconazole at
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole at 400 mg twice daily on the first day and 200 mg twice daily on the second day
Study: 16723553
Drug: Fluconazole at
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole at 400 mg on the first day and 200 mg on the second day
Study: 16723553
Drug: Control (Ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Ibuprofen alone)
Study: 11150432
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with etoposide, bleomycin, and high or standard dose cisplatin
Study: 11150432
Drug: Biopsy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsy and chemotherapy without tumor resection
Study: 11150432
Drug: Resection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resection at diagnosis followed by chemotherapy
Study: 11150432
Drug: Biopsy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biopsy followed by chemotherapy and post-chemotherapy tumor resection
Study: 8121966
Drug: SSRIs (fluoxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (fluoxetine, sertraline)
Study: 3314790
Drug: 0.9 mw
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mw continuous wave HeNe laser treatment
Study: 17626986
Drug: Nadroparin (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (therapeutic doses throughout treatment)
Study: 17626986
Drug: Parnaparin (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parnaparin (therapeutic doses for the first month, then prophylactic phase at half dose)
Study: 15793400
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 2% lidocaine hydrochloride
Study: 12606735
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg adefovir dipivoxil
Study: 12606735
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg adefovir dipivoxil
Study: 31310470
Drug: 0.04 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg/kg lorazepam per os (PO) twice before the operation
Study: 23520670
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anxiolytic premedication)
Study: 25476995
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral ibandronate
Study: 25476995
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg i.v. ibandronate
Study: 22251482
Drug: FBS0701 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBS0701 at 14.5 mg/kg/d